Keys et al. [5] (cervix)
|
Cis 40 mg/m2 q wk X 6 concurrent
|
75 Gy to pt A
|
0 deaths 1 Grade 3&1 Grade 4 CVT (NOS)
|
183
|
Benedetti et al. [3] (cervix)
|
Cis 40–80 mg/m2 q wk X 6–8 concurrent
|
45–50 Gy WP 20–30 Gy Low Dose Rate
|
0 deaths
|
201
|
Morris et al. [2] (cervix)
|
Cis 75 mg/m2 and 5-FU 4000 mg/m2 q wk X 3 concurrent
|
85 Gy to pt A
|
1 death (NOS)
|
193
|
Pearcey et al. [6] (cervix)
|
Cis 40 mg/m2 q wk X 5 concurrent
|
80 Gy to pt A
|
1 death (SBP) 3 Grade 3 CVT (NOS)
|
127
|
Peters et al. [7] (cervix)
|
Cis 70 mg/m2 and 5-FU 1000 mg/m2 q wk X 4 concurrent
|
4930 WP @ 170 cGy/day
|
1 death (Bilateral ureteral obstruction)
|
127
|
Rose et al. [8] (cervix)
|
Cis 40 mg/m2 q wk X 6 concurrent or Cis/5-FU/Hydroxyurea or Hydroxyurea
|
80 Gy to pt A
|
0 deaths 2 Grade 3 CVT (NOS), with 3 drug regimen
|
526
|
Malfetano et al. [4] (cervix)
|
Cis 1 mg/Kg q wk with XRT
|
45 Gy PA, WP 4–5000 cGy and 3–4000 cGy Low Dose Rate
|
2 Grade 5 CVT (from PE)
|
67
|